Holen Sie sich die Stockscreener-App
19.95
0.65%
-0.13
Handel nachbörslich:
19.95
Jade Biosciences Inc Aktie (JBIO) Neueste Nachrichten
Orbimed Advisors LLC Sells 346,152 Shares of Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences Ord Shs (JBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
JBIO|Jade Biosciences Ord Shs|Price:20.379|Chg%:+0.299 - TradingKey
Affinity Asset Advisors LLC Decreases Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences, Inc. Revenue Breakdown – NASDAQ:JBIO - TradingView
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ja - GuruFocus
Jade Biosciences Company Profile & Introduction - Moomoo
Paradigm funds disclose significant Jade Biosciences (JBIO) ownership in Schedule 13G - Stock Titan
Jade Biosciences Inc. (JBIO) Climbs 1.67% as Stock Tests Near Resistance at $22.37IV Rank - dars.gov.et
Jade Biosciences Inc. (JBIO) Holds Steady Near Key Resistance as Trading Volume Remains CalmHull Moving Average - DonanımHaber
Price to earnings forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Price to book forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Price to sales forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Enterprise value to EBIT forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Enterprise value to revenue forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Janus Henderson holds 6.27M JBIO shares, reporting 10.6% stake (JBIO) - Stock Titan
JBIOJade Biosciences Inc Options - Finviz
Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued? - Sahm
Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics - Moomoo
JBIO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineRevenue Report - dars.gov.et
Jade Biosciences Inc. (JBIO) Slips 3.16%: Testing Key Support Amid Sector VolatilityIndex Put Call - dars.gov.et
Jade BiosciencesParagon Barred From New Ca - Moomoo
Jade Biosciences Secures Exclusive Antibody License Agreement - TipRanks
Jade Biosciences Secures Global Exclusive Antibody License From Paragon Therapeutics With Milestones Up to $22M - TradingView
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? - Yahoo Finance
Jade Biosciences (JBIO) Steady Climb: Testing Resistance After Modest GainWedge Breakout - dars.gov.et
Jade Biosciences, Inc.(NasdaqCM:JBIO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM:JBIO) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 3000 Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 2500 Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 3000E Value Benchmark - marketscreener.com
5 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 2000 Value Benchmark - marketscreener.com
Form 4 Jade Biosciences Inc For: 26 June By Investing.com - Investing.com India
Jade Biosciences (JBIO) director receives 47,675 stock options at $21.81 strike - Stock Titan
Jade Biosciences (JBIO) director Mark Eisner files initial Form 3 - Stock Titan
Form 3Initial statement of beneficial ownership of securities - ADVFN
Jade Biosciences appoints Mark Eisner to board of directors By Investing.com - Investing.com Nigeria
Jade Biosciences appoints Mark Eisner to board of directors - Investing.com
Jade Biosciences Adds Veteran Biopharma Leader to Board - TipRanks
Jade Biosciences Appoints Dr. Mark Eisner to Board, Strengthening Leadership for Autoimmune Therapy Pipeline - Minichart
Jade Biosciences appoints Mark Eisner to its Board and Nominating & Corporate Governance Committee - TradingView
Immunology leader Mark Eisner joins Jade Biosciences (NASDAQ: JBIO) board - Stock Titan
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors - The Manila Times
Jade Biosciences, Inc. Actuals & Estimates (NASDAQ:JBIO) - TradingView
JBIO Forecast — Price Target — Prediction for 2027 - TradingView
Jade Biosciences Inc. (JBIO) Surges 16.77%: Breaking Above Key LevelsPut Dominated - dars.gov.et
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Jade Biosciences (JBIO) Surges 5.6% as Biotech Momentum BuildsAAII Neutral - dars.gov.et
UBS Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $45 - Moomoo
UBS Initiates Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $45 - Moomoo
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):